Switching to Second-Line Therapy Versus First-Line Antiretroviral
In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.
Read More
Survey: Two-Thirds of US Adults Have Not Received HIV Testing
Despite being recommended at least once among all persons aged 13-64 years old by the CDC, notably few respondents have ever been tested for HIV.
Combatting Virologic Failure in Children with HIV using Targeted Drug Resistance Testing
Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.
Eight-Week Cabotegravir Injection Has HIV PrEP Potential
Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.
Doravirine Benefits HIV-1 Patients with Common RAMs
A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.
Gaining Insights into Islatravir and Doravirine
Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.
Watch
UNAIDS Report: Inequality and Coronavirus Risk a Decade of HIV Progress
A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.
Clinics Test Long-Acting HIV Therapy Implementation Strategies in Cabotegravir-Rilpivirine Trial
CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.
Eravacycline Realizes Successful Clinical Endpoint in OPAT Facilities
The antibacterial is efficacious in a majority of patients in a small study.
Antibiotic Scorecards Lead to More Appropriate Prescribing
Antimicrobial stewardship education was conducted with de-identified provider-specific prescribing scorecards.
MGB Biopharma Announces Successful Phase 2 C. difficile Candidate Trial
A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.
Cefepime-Enmetazobactam Shows Promise for ESBL-Producing Enterobacteriaceae
The novel drug combines a fourth-generation cephalosporin with a novel extended-spectrum β-lactamase inhibitor.
Fosfomycin Does Not Demonstrate Non-Inferiority for E. Coli. Bacteremic UTI
Drug resistance has physicians racing to find alternative therapies for many infections. In a new non-inferiority study, fosfomycin was inferior to more common therapies.
Gram-Negative Infections Successfully Treated with Ceftazidime-Avibactam
Gram-negative bacteria can cause infections, are resistant to multiple drugs, and are increasingly resistant to most available antibiotics, the CDC says.
Oral Ibrexafungerp Effective & Well-Tolerated in FURI Phase 3 Trial
Oral ibrexafungerp could cut hospital stays for patients with invasive candidiasis infections.
Comparing Sensitivities: RT-PCR Versus Rapid Influenza Diagnostic Test
It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.
Study Finds Variability in Cefiderocol Pharmacokinetics
Investigators say they consider cefiderocol a candidate for therapeutic drug monitoring.
RESTORE-IMI 2: Imipenem/Cilastatin Relebactam Non-inferior to Piperacillin/Tazobactam for HABP/VABP
The data were released as part of the now-cancelled European Congress of Clinical Microbiology and Infectious Diseases.
Is Risk of Colorectal Cancer Linked to Certain Blood Infections?
Previous research has suggested an association between bacteria from the Bovis group streptococci, Clostridium septicum and colorectal cancer
Tracing Scarlet Fever Transmission in English Classrooms
Investigators have hypothesized that scarlet fever transmission is driven by pediatric cases with symptomatic disease.
Vaccinoscopie Europe Survey Evaluates Parental Views on Vaccination
A new survey found that parents in Spain were the most supportive of vaccinations when compared with their counterparts in 4 other European countries.
Study Finds Pets Not a Substantial Reservoir for Human Multidrug-Resistant Infections
Whole genome sequencing revealed little overlap between MDROs found in pets and pet owners.
TB Screening Among People Living With HIV in PEPFAR Countries
A poster presented at CROI 2020 examined rates of TB screening among people living with HIV in PEPFAR supported countries.
People Facing HIV Stigma Are Less Likely To Make Their Next Care Visit
Patients facing HIV stigma may encounter difficulties with retention in care.
George Hanna, MD: Islatravir Presentations at CROI 2020
George Hanna, MD, vice president and therapeutic head of infectious diseases at Merck Laboratories, discusses data from CROI 2020 on islatravir.
Virus-Delivered Anti-HIV Antibody Shows Promise in NIH Study
An antibody gene delivered by a harmless virus produced anti-HIV antibodies for a sustained period.
Timothy Skalland, PhD: Examining HIV Incidence and Viral Burden at the Community Level in the PopART Trial
Higher HIV incidence is associated with higher viral burden, according to results from the PopART trial presented at CROI 2020.
Kenneth Mayer, MD: Safety and Tolerability of Once-Daily BIC/FTC/TAF for Postexposure Prophylaxis
A poster on antiviral PEP safety and tolerability was presented at CROI 2020.
Kenneth Mayer, MD: Reasons for Suboptimal PrEP Use Among At-Risk US MSM
A new study examining the reasons for suboptimal PrEP use among MSM was presented at CROI 2020.
Trial Data Released for Investigational HIV-1 Capsid Inhibitor
Data from clinical and preclinical studies on the use of the investigational HIV-1 capsid inhibitor GS-6207 were presented via 3 posters at CROI 2020.
